Provided by Tiger Trade Technology Pte. Ltd.

Provident

23.30
-0.0200-0.09%
Post-market: 23.300.00000.00%16:10 EDT
Volume:766.49K
Turnover:17.83M
Market Cap:3.04B
PE:9.72
High:23.62
Open:23.56
Low:23.00
Close:23.32
52wk High:25.49
52wk Low:17.69
Shares:130.62M
Float Shares:126.13M
Volume Ratio:1.15
T/O Rate:0.61%
Dividend:0.96
Dividend Rate:4.12%
EPS(TTM):2.40
EPS(LYR):2.23
ROE:11.14%
ROA:1.25%
PB:1.05
PE(LYR):10.44

Loading ...

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

GlobeNewswire
·
May 31

HENLIUS Shares Surge in Afternoon Trading Following Key Clinical Milestone and Upcoming Data Release

Stock News
·
May 29

Dudick Promoted to Svp, Team Leader at Provident Bank

THOMSON REUTERS
·
May 27

Press Release: Dudick Promoted to SVP, Team Leader at Provident Bank

Dow Jones
·
May 27

Press Release: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 27

Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List

prnewswire
·
May 27

Provident Financial extends executive chairman Christopher Martin compensation agreement to May 2028

Reuters
·
May 27

Provident Financial Services shareholders elect four directors at annual meeting

Reuters
·
May 22

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

GlobeNewswire
·
May 22

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

GlobeNewswire
·
May 22

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

GlobeNewswire
·
May 22

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

GlobeNewswire
·
May 22

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

GlobeNewswire
·
May 22

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

GlobeNewswire
·
May 22

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

GlobeNewswire
·
May 22

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

GlobeNewswire
·
May 22

Kinterra Capital Secures US$75 Million to Advance White Pine Copper to FID Following PFS Progress and Royalty Framework Update

prnewswire
·
May 20

Anson Resources Completes Pre-Feasibility Study for US Lithium Project, Shares Fall 6%

MT Newswires Live
·
May 19

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

GlobeNewswire
·
May 16

Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst

Benzinga
·
May 16